Acumen Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held by Acumen Pharmaceuticals, Inc. on June 3, 2026. The company is an emerging growth company incorporated in Delaware, with its common stock trading on the Nasdaq Global Select Market under the symbol ABOS.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Of the 72,227,580 shares outstanding, 57,051,456 shares (approximately 78.99%) were present or represented by proxy. The stockholders voted on three proposals:
- Proposal 1 (Election of Directors): Three Class II directors were elected to serve until the 2029 annual meeting.
- George Golumbeski, Ph.D.: Elected (37,305,711 votes for).
- Derrell Porter, M.D.: Elected (30,926,494 votes for).
- Laura Stoppel, Ph.D.: Elected (30,812,559 votes for).
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 (56,934,900 votes for).
- Proposal 3 (Equity Incentive Plan): Stockholders approved the Amended and Restated 2021 Equity Incentive Plan (30,731,776 votes for).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, or contingencies. The document serves solely to disclose the outcomes of the shareholder vote.
Key Facts for Investor Verification
- Verify the specific terms and share limits of the newly approved Amended and Restated 2021 Equity Incentive Plan.
- Confirm the tenure and responsibilities of the newly elected Class II directors (Golumbeski, Porter, Stoppel).
- Review the definitive proxy statement filed on April 23, 2026, for detailed background on the proposals.
- Note the significant number of broker non-votes (19,676,925) on the director election and equity plan proposals.